|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/192 | (2006.01) |
| A61K 47/18 | (2017.01) | ||
| A61K 9/00 | (2006.01) | ||
| A61P 1/16 | (2006.01) |
| (11) | Patento numeris | 3518916 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17777046.8 |
| Europos patento paraiškos padavimo data | 2017-09-28 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-08-07 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-07-07 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2017/074701 |
| Data | 2017-09-28 |
| (87) | Numeris | WO 2018/060372 |
| Data | 2018-04-05 |
| (30) | Numeris | Data | Šalis |
| 1659438 | 2016-09-30 | FR |
| (72) |
LARUELLE, Claude , FR
BONNAFOUS, Ludovic , FR
|
| (73) |
Nashpharm ,
18 avenue Bellevue, 06270 Villeneuve Loubet,
FR
|
| (54) | COMPOSITION COMPRENANT AU MOINS UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'ELAFIBRANOR SOLUBLE EN MILIEUX AQUEUX PRESENTANT UNE ABSORPTION INTESTINALE AMELIOREE |
| COMPOSITION COMPRISING AT LEAST ONE WATER-SOLUBLE PHARMACEUTICALLY ACCEPTABLE SALT OF ELAFIBRANOR HAVING IMPROVED INTESTINAL ABSORPTION |